Clinical Trial Update: Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of lenvatinib (18 mg vs 14 mg) in combination with everolimus for renal cell carcinoma has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-03-05